SCHEMBL1442885

SCHEMBL1442885

N=C(N)Cc1cccnc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.58
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
CHRNA7 P36544 1/20 0.52
RECQL P46063 1/20 0.51
ESR1 P03372 1/20 0.50
CYP19A1 P11511 1/20 0.50
CYP2A6 P11509 1/20 0.48
CYP2D6 P10635 1/20 0.48
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
HRH1 P35367 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CHRNB2 P17787 2/20 0.46
CHRNA4 P43681 2/20 0.46
MAPK8 P45983 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16571554 0.98 NAPRT (0.56) NAPRTCYP1A2CYP3A4CYP2C9CHRNA7
SCHEMBL794394 0.80 NAPRT (0.69) NAPRTCYP1A2CYP3A4CYP2C9CHRNA7
SCHEMBL30940201 0.80 NAPRT (0.58) NAPRTCYP1A2CYP3A4CYP2C9CHRNA7
SCHEMBL25905487 0.80 NAPRT (0.58) NAPRTCYP1A2CYP3A4CYP2C9CHRNA7
SCHEMBL5902378 0.80 NAPRT (0.58) NAPRTCYP1A2CYP3A4CYP2C9CHRNA7
SCHEMBL29701327 0.80 NAPRT (0.69) NAPRTCYP1A2CYP3A4CYP2C9CHRNA7
Hydrochloric Acid SCHEMBL2673018 0.78 NAPRT (0.67) NAPRTCYP1A2CYP3A4CYP2C9CHRNA7
Hydrochloric Acid SCHEMBL6992571 0.78 NAPRT (0.56) NAPRTCYP1A2CYP3A4CYP2C9CHRNA7
SCHEMBL3524137 0.77 NAPRT (0.55) NAPRTCYP1A2CYP3A4CYP2C9CHRNA7
SCHEMBL5634650 0.77 NAPRT (0.55) NAPRTCYP1A2CYP3A4CYP2C9CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037059-A1 GYRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-02-09 US disclosed
US-9481675-B2 Gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-01 US disclosed
US-20130079323-A1 GYRASE INHIBITORS TRIUS THERAPEUTICS, INC. (US) 2013-03-28 US disclosed
EP-2475666-A2 GYRASE INHIBITORS Trius Therapeutics, Inc. (US) 2012-07-18 EP disclosed
WO-2011032050-A2 GYRASE INHIBITORS TRIUS THERAPEUTICS, INC. (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037059-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B NAPRT 693/4885CYP1A2 571/4885CYP3A4 430/4885
US-20130079323-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B NAPRT 693/4885CYP1A2 571/4885CYP3A4 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.